Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

PaperCitations, authors & open-access status

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 518 citations, 2023 year and closed oa status.

518
Citations
2023
Year
closed
OA Status

Related on ScholarIQ

Neeraj Agarwal
Author
The Lancet
Journal
Prostate Cancer Treatment and Research
Topic
Prostate Cancer Treatment and Research
Topic
PARP inhibition in cancer therapy
Topic
Prostate Cancer Diagnosis and Treatment
Topic
470M+ articles · free account